A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 800 participants.
Also called NCT07082114
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 800 participants
- Registry
-
NCT07082114
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07082114. Randomized; quadruple masking; primary purpose treatment. Start 2025-07-14 (actual); primary completion 2027-02-16 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- HDM1002 100 mg
- Intervention (Drug)
- HDM1002 200 mg
- Intervention (Drug)
- HDM1002 400 mg
- Intervention (Drug)
- Dapagliflozin (DAPA)
- Lead sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct07082114- Content hash
997b7baefd3cc8ef7f73465e4188695b2eec9f97149eb314c62b971927046a44